TRAF6 and rheumatoid arthritis: In preclinical in vivo mouse models, C25-140, an inhibitor of the TRAF6-Ubc13 interaction, can reduce NF-κB activation, improving the disease outcomes for autoimmune psoriasis and rheumatoid arthritis [119].